Assura (AGR) M&A Announcement (Q&A) summary

Deal rationale and strategic fit

• Acquisition of 14 fully operational UK private hospitals for £500 million accelerates diversification into the private healthcare sector, aligning with strategy to be the leading UK healthcare property investor and developer.

• The deal responds to growing demand for private healthcare due to NHS strain and socio-demographic trends, supporting portfolio diversification and return profile.

• Strengthens relationships with all five Tier 1 private providers, enabling long-term partnership opportunities and future growth.

• 20% increase in rent roll and unique position as a diversified healthcare REIT with exposure to both NHS and private markets.

• Enhances scale and cements position as a leading UK healthcare property investor and developer.

Financial terms and conditions

• Headline price of £500 million: £100 million in new shares to seller (subject to six-month lock-in), £266 million refinanced debt, and £134 million from cash/RCF.

• Initial yield on cost is 5.9%, higher than the existing portfolio average of 5.17%, with day one rent cover of 2.3x.

• Proforma property value increases to £3.2 billion; proforma LTV at 48%, with a target to reduce below 45% and net debt/EBITDA below 9x over 18–24 months via disposals.

• New £266 million term loan at 110bps margin, maturing August 2026, with extension options and expected swap rate of ~4%.

• No stamp duty payable due to deal structure; all financial covenants remain compliant post-acquisition.

Synergies and expected cost savings

• All assets on fully tenant repairing and insuring leases, with occupiers funding all CapEx, including environmental upgrades.

• Limited incremental overhead (£600-800k per annum) and opportunity to restructure and unlock further savings.

• Potential for further collaboration with operators and asset enhancement, including extensions and sustainability upgrades.

• Disposal programme and capital recycling to strengthen balance sheet.